Our mission is to deliver solutions and bring hope to as many people as possible.

Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.

More info

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team.

The application of a unified work methodology, with a focus on quality in everything we do.

More info

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

CREATING STRONG VALUE IN
BIOPHARMACEUTICALS

mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals.

ABOUT
mAbxience

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

mAbxience is a fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Partnerships

mAbxience has successfully established alliances around the world with key partners, allowing patients access to our quality products across the globe.

We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial environment.

mAbNews

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

03/31/2021

The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

03/25/2021

Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]

ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab

02/15/2021

They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix

Who we are

mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars.

Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world.

CREATING STRONG VALUE IN
BIOPHARMACEUTICALS

ABOUT
mAbxience

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

Partnerships

mAbNews

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab

Who we are

mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars.

mAbNEWS

European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

What’s next? Meet us at...

Bio-Europe Spring 2021

Partnerships

CREATING STRONG VALUE INBIOPHARMACEUTICALS

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

Partnerships

CREATING STRONG VALUE IN
BIOPHARMACEUTICALS